Please upgrade your browser.
News of a Pfizer sponsored clinical trial.
Axitinib (AG-013736) is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. We aimed to assess the activity and safety of axitinib in patients with metastatic renal-cell cancer who had failed on previous cytokine-based treatment.
When he was diagnosed with kidney cancer last year, Dave deBronkart needed an easy way to keep his far-flung friends and family updated.
His topic will be "The Future of Cancer Care."
These products look set to target some of the "big" cancers, with launches for vaccines against renal cell carcinoma, melanoma, prostate, non-small cell lung and colorectal cancer.
Patient Roger Willcocks will now receive a drug that was denied to him by the NHS.
The University of Michigan is presenting a symposium on the treatment options for patients and families dealing with Kidney Cancer
Sponsored by the UM Comprehensive Cancer Center, Department of Urology, Department of Internal Medicine Division of Hematology/Oncology.
A UT Southwestern Medical Center physician and other researchers have developed a unique statistical model that predicts the probability of a patient being cancer free 12 years after initial surgical treatment.
Combination failed to prevent disease progression or improve survival.
|Powered by NeonCRM|